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Abbreviations 
APC  Argon plasma coagulation  
BE  Barrett’s esophagus 
CLE  columnar lined esophagus 
CT  computerized tomography 
EAC  esophageal adenocarcinoma 
ER  endoscopic resection 
EUS  endoscopic ultrasound  
FNA   fine needle aspirate 
GEJ  gastro-esophageal junction 
H pylori helicobacter pylori  
HGD   high grade dysplasia 
LGD  low grade dysplasia 
PDT  photodynamic therapy  
PET  positron emission tomography 
RFA   radiofrequency ablation 
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Abstract 
Barrett’s esophagus (BE), a common condition, is the only known precursor to esophageal 
adenocarcinoma (EAC). There is uncertainty about the best way to manage BE, since most people 
with BE never develop EAC and most patients diagnosed with EAC have no preceding diagnosis of 
BE. Moreover, there have been recent advances in knowledge and practice about the management 
of BE and early EAC. To aid clinical decision-making in this rapidly moving field, Cancer Council 
Australia convened an expert working party to identify pertinent clinical questions. The questions 
covered a wide range of topics including endoscopic and histologic definitions of BE and early EAC; 
prevalence, incidence, natural history and risk factors for BE; and methods for managing BE and 
early EAC. The latter considered modification of lifestyle factors; screening and surveillance 
strategies; and medical, endoscopic and surgical interventions. To answer each question, the 
working party systematically reviewed the literature and developed a set of recommendations 
through consensus. Evidence underpinning each recommendation was rated according to quality 
and applicability.  
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Introduction 
Barrett’s Esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), 
a cancer with a rapidly rising incidence. Most people with BE never develop EAC however, 
and most patients diagnosed with EAC have no preceding diagnosis of BE. Thus, there is 
uncertainty about the best way to manage this condition.  
These Guidelines about BE and early EAC are aimed at gastroenterologists, pathologists, 
surgeons and physicians, and other members of multi-disciplinary teams to which patients 
with BE and EAC are referred. The Guidelines will also be relevant to primary care 
practitioners and patients diagnosed with this condition. The need to develop Australian 
guidelines for the management of BE and early EAC was identified as a priority by a strategic 
partnership of clinicians, researchers, patients and policy makers initiated by Cancer Council 
NSW in 2011. 
Information covered by the Guidelines includes: 
1. Endoscopic and histologic definitions of BE and early EAC  
2. Prevalence, incidence, natural history and risk factors for BE  
3. Management of BE and early EAC, including modification of lifestyle factors, 
screening, surveillance, and medical, endoscopic and surgical interventions. 
The evidence summaries and recommendations are provided separately for BE without 
dysplasia and BE with dysplasia and/or early cancer, but do not extend to the management 
of invasive EAC. The recommendations contained herein should not override good clinical 
judgement. However they do represent consensus views of expert practitioners and accord 
with international practices. This publication represents a summary of more extensive 
material hosted on the Cancer Council Australia Wiki platform 1 which explores the reasons 
underlying the recommendations in more detail.  
Methods 
Guideline development was facilitated by Cancer Council Australia, which managed the 
project and provided in-kind support. No external funding was received for guideline 
development. 
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The guidelines were developed by a multidisciplinary working group and used standard 
methodology 2. A series of clinical questions were developed to be answered based on 
systematic reviews. In consultation with the working group, systematic search strategies 
were developed by project officers using the PICO framework and limits and exclusion 
criteria were pre-defined to complete the systematic review protocol. Databases searched 
included The Cochrane Library, PubMed, Embase, Trip Database, Econlit, National Health 
Service (UK) Economic Evaluation Database, the National Guideline Clearinghouse, the 
National Comprehensive Cancer Network and the National Institute for Health and Clinical 
Excellence, Scottish Intercollegiate Guidelines Network and Canadian Medical Association. 
Search results were screened by project officers and relevant articles were sent to topic 
authors for critical appraisal with respect to level and quality of evidence, effect size, and 
clinical importance and relevance. The level of evidence for each article was assigned 
according to the National Health and Medical Research Council of Australia (NHMRC) 
Evidence Hierarchy (Table 1).  
Each topic author summarized the relevant body of literature and then developed 
recommendations. Each recommendation was assigned a grade by the working group taking 
into account the volume, consistency, generalizability, applicability and clinical impact of the 
supporting evidence (Table 2). When there was insufficient evidence to make a specific 
recommendation but consensus amongst experts about the advisability of making a 
clinically relevant statement, the working group formulated “practice points” to guide 
clinical practice. The working group also reviewed comparable international guidelines to 
calibrate the recommendations.  
The draft guidelines underwent public consultation in June and July 2014. Feedback was 
reviewed by topic authors and the working group. Subsequent changes to the draft were 
agreed by consensus of the working group and the final guidelines were released August, 
2014. The Wiki guidelines will be reviewed annually and updated as required. 
 
Guidelines for BE without dysplasia 
What is the definition of BE and how is it described?  
8 
 
BE is a premalignant condition of the esophagus defined as the presence of metaplastic 
columnar epithelium 3 which appears endoscopically as salmon pink mucosa extending 
above the gastro-esophageal junction (GEJ) and into the tubular esophagus, thereby 
replacing the normal stratified squamous epithelium. 3 4 An accurate diagnosis of BE 
depends on the endoscopic recognition of the anatomic landmarks at the GEJ and 
squamocolumnar junction. 5 Using the Prague C & M (Circumferential and Maximal) criteria 
proposed by the International Working Group for the Classification of Esophagitis 6, the 
landmark for the GEJ is the proximal end of the gastric folds. 
The metaplastic columnar mucosa can be one of three types: gastric-fundic type, cardiac 
type and intestinal-type. 7 There remains disagreement as to the histologic features of the 
columnar mucosa necessary to define BE, as reflected in the differing definitions given in 
European and American guidelines 8 9 10 11. For the Australian guidelines however, the 
presence of intestinal metaplasia with morphologically typical goblet cells was considered 
necessary for the diagnosis of BE.  
Biopsies from the tubular esophagus containing columnar mucosa without intestinal 
metaplasia should be given a descriptive diagnosis (e.g. columnar mucosa without intestinal 
metaplasia), but it is currently recommended that these are not diagnosed as BE until the 
biological significance of this entity is clarified. 
Intestinal metaplasia occurring in isolation at the gastro-esophageal junction or cardia 
without metaplasia in the tubular esophagus is not considered BE. It may be a precursor to 
carcinoma, but the risk is low and surveillance is not warranted. 12, 13 However goblet cells 
noted in a GEJ biopsy can be confirmed to be intestinal metaplasia in columnar lined 
esophagus if the particular biopsy fragment shows native esophageal structures such as 
submucosal glands and/or ducts. 
Practice points  
To identify patients at increased risk of neoplastic progression, BE is defined as metaplastic 
columnar mucosa in the tubular esophagus, with intestinal metaplasia proven histologically.  
Biopsies to confirm intestinal metaplasia should be performed when any length of possible 
BE is seen extending above the gastro-esophageal junction.  
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The extent of BE should be described using the Prague C & M Criteria.  
 
What is the optimal tissue sampling at endoscopy for diagnosis of BE?  
Intestinal metaplasia can be patchy and may not be consistently sampled with endoscopic 
biopsies. 14 (Level of Evidence IV). Advancements in chromoendoscopy (methylene-blue, 
indigo carmine, and acetic acid), endoscope digital enhancements (Narrow-Band Imaging, i-
SCAN, Fujinon Intelligent Chromo Endoscopy) and enhanced-magnification have not been 
shown to be superior to the currently accepted practice of random four-quadrant biopsies 
at 2cm intervals. 15, 16 17 (Levels of evidence I, II, IV respectively), however the diagnostic 
yield may be higher with increasing number of biopsies. (Level of evidence IV) 18 Jumbo 
biopsy forceps have not been shown to be superior to standard capacity forceps in 
obtaining adequate biopsy samples (Level of evidence II) 19 Office-based unsedated 
transnasal endoscopy using pediatric biopsy forceps is well-tolerated and may emerge as a 
cost-effective strategy. (Level of evidence II) [20-22 
Recommendation 
Random four-quadrant biopsies at 2cm intervals are the mainstay for tissue sampling. 
(Recommendation grade B) 
Practice points  
Focal abnormalities such as ulcerated or nodular lesions should be targeted with biopsies 
and labeled before random biopsies from the rest of the mucosa as minor biopsy-related 
bleeding is common and may impair endoscopic views.  
Technological advancements in chromoendoscopy, digital enhancements and enhanced-
magnification complement rather than replace random four-quadrant biopsies at 2cm 
intervals. Biopsies obtained every 2cm should be placed into separate jars which are labeled 
according to the distance from the incisors, while biopsies from the gastro-esophageal 
junction and cardia can also be specifically labelled as such.  
Are there biomarkers for the diagnosis of BE?  
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Numerous biomarkers have been proposed to aid the diagnosis of BE. Estimates of 
diagnostic accuracy have been reported for: tissue biomarkers, including cytokeratin 
profiling23-29, immunohistochemical biomarkers to detect goblet cells such as mucin 
immunostaining30, 31, and stress response protein AG232; a serum biomarker (G1733); and a 
non-endoscopic capsule sponge device to collect cytology samples for Trefoil factor 3 
immunohistochemistry (TFF3),34, 35 (Diagnostic accuracy level of evidence II – III-3). These 
studies provide insufficient evidence to recommend any biomarkers to supplement or 
replace standard practice use of endoscopy and histopathology due to: study designs with a 
high risk of bias; wide variation in accuracy estimates across studies; and no comparison 
with current standard practice. 
Recommendation 
There is insufficient evidence to recommend cytokeratins, MUC, G17 or AG2 to aid BE 
diagnosis. (Grade D).  
There is insufficient evidence to recommend the non-endoscopic capsule sponge device 
with TFF3 for BE screening. (Grade C). 
What is the prevalence of BE in the Australian population in comparison with other 
populations?  
Globally, the prevalence of BE is low (<5%) but is higher in selected groups such as those 
with gastro-esophageal reflux disease (>15%). There are no studies describing the 
prevalence of BE in an asymptomatic, unselected Australian population. One small study 
suggests a high prevalence in high-risk patient populations. 36 A data linkage study 
conducted in one Australian health-care region reported prevalence rates at each of three 
time points as 0.42% (1990), 2.3% (1998), and 4.2% (2002). 37 International studies suggest 
prevalence varies significantly by ethnicity (e.g. Asians <1% prevalence) and gender (more 
common in males).  
Which factors best predict the risk of developing BE?  
Risk factors for BE have been assessed in more than 50 studies. All studies have been 
observational, and most have been case-control studies of variable quality. From these 
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studies, the major risk factors identified include age 38, male sex 39, history of frequent 
gastro-esophageal acid reflux 40, central obesity 41, smoking 42 and family history 43. (Level of 
evidence III-3, IV). A few studies have conducted serological assays comparing the 
prevalence of anti-H pylori antibodies between BE cases and controls, reporting risk 
reductions of about 50% for persons with past infection with H pylori. 44, 45 There is no 
evidence that alcohol consumption or dietary or nutritional factors influence risk 46, 47.  
Recommendation  
Clinical assessment of a person’s future risk of BE should consider their age, sex, history of 
gastro-esophageal acid reflux, waist-hip ratio or other measures of central adiposity, 
smoking history, and family history of esophageal adenocarcinoma and/or BE (Grade B)  
What is the incidence of neoplasia in patients with BE? 
Five population-based, prospective studies with large sample sizes and complete follow-up 
of patients with uncomplicated BE with no dysplasia have reported progression rates to 
high-grade dysplasia (HGD) or adenocarcinoma of 2.2-2.6/1000 person-years (py) in 
Northern Ireland 48, 49, 3.3/1000 py in the Netherlands 50, 1.2/1000 py in Denmark 51 and 
3/1000 py in the United Kingdom 52. Meta-analyses of high-quality studies derived similar 
estimates of progression risks 53 54. 
What are the risk factors for progression from non-dysplastic BE to high-grade dysplasia or 
adenocarcinoma?  
Increased rates of progression from non-dysplastic BE to HGD or adenocarcinoma have been 
associated with patient factors (age, sex, smoking), endoscopic appearance (greater 
segment length), and aneuploidy. 48, 55-58 (Level of Evidence III-2). There is observational 
evidence that regular users of proton pump inhibitors (PPI), non-steroidal anti-inflammatory 
drugs (NSAIDs) and statins may have lower rates of progression from BE to cancer. 59-64 
(Level of evidence: II, III-2, III-3)  
Recommendation 
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Clinical assessment of future risk of high-grade dysplasia or adenocarcinoma in the setting 
of non-dysplastic BE should consider age, sex, smoking history and endoscopic findings 
(Grade C).  
For which populations is screening for BE cost-effective?  
In line with accepted epidemiologic practice, these guidelines reserve ‘screening’ to describe 
the process of identifying new cases of disease in an unselected population, whereas 
‘surveillance’ describes the systematic follow-up of patients with known disease at periodic 
intervals as part of an early detection strategy to prevent progression to cancer. 
There is no evidence to support population screening for BE. However, health economic 
studies generally suggest that one-off screening of 50-year old men with gastro-esophageal 
reflux disease might be cost-effective. Both the cytosponge 65 and ultra-thin endoscopy 66 
may be more cost-effective compared to standard endoscopic screening. General 
population screening, even if conducted coincident with colonoscopy screening, is not cost-
effective.  
What is appropriate medical systemic therapy for symptoms associated with BE?  
Medical systemic therapy for patients with BE aims to control symptoms and reduce the risk 
of complications. Uncomplicated BE is not a cause of symptoms (indeed patients with BE 
may have reduced sensitivity to esophageal acidification); rather these are due to the 
symptoms of gastro-esophageal reflux. 67 Acid suppression with proton pump inhibitors 
(PPI) is the most effective systemic therapy for reflux symptoms in patients with BE and will 
control symptoms in most patients with a durable effect over years (Level of Evidence II, IV) 
68, 69 70-72 73-75 76-78 Higher than standard doses of PPI may be required to control symptoms in 
a proportion of patients. (Level of Evidence IV) 79-81 
Recommendation 
Symptomatic patients with BE should be treated with Proton Pump Inhibitor therapy (PPI), 
with the dose titrated to control symptoms. (Grade C)  
Are there any medical or surgical interventions that cause regression of BE?  
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Regression of BE is defined by a reduction in the length or area of metaplastic columnar 
epithelium, however the significance of regression in BE is unclear. There are insufficient 
data to indicate that regression leads to reduced incidence of EAC . The degree of Barrett’s 
regression appears largest amongst patients undergoing anti-reflux surgery although a 
randomized trial comparing surgical and medical therapy found no significant differences. 76  
Combined analysis of randomized trials has not demonstrated BE regression with medical 
therapy. 82 (Level of evidence I).  
Recommendation 
There is insufficient evidence to recommend the use of acid suppressive therapy for the 
regression of BE (Grade B). 
There is insufficient evidence to recommend anti-reflux surgery for the regression of BE 
(Grade C).  
Practice point  
Acid suppressive therapy and anti-reflux surgery can be used to control symptoms and heal 
reflux esophagitis in patients with BE. There is insufficient evidence to recommend high 
dose (twice daily) acid suppressive therapy when symptom control or mucosal healing is 
achieved with standard dosing.  
Is there a role for ablative therapy to treat BE? 
Various endoscopic techniques have been investigated for eradicating BE epithelium, 
including those that deliver focal ablation (argon plasma coagulation (APC), laser heater 
probe, and endoscopic mucosal resection (EMR)) and those that ablate broad fields 
(photodynamic therapy (PDT) and radiofrequency ablation (RFA)).  
APC is a widely available monopolar electrocautery method. Randomized trials show that 
medically treated patients and patients with prior fundoplication can be cleared of Barrett’s 
mucosa whereas control patients do not show significant regression. 83-85  
PDT involves administration of a photosensitiser drug (typically oral aminolevulinic acid, or 
IV photofrin) and subsequent exposure of the Barrett's mucosa to a laser light. Because of 
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potentially severe skin sensitivity, the subject must remain in a darkened environment, 
restricting use of this technology to cooler climate countries.  
RFA involves placement of a balloon catheter in the esophagus, through which 
radiofrequency energy is delivered allowing treatment of a 3cm circumferential segment of 
the esophagus. Side effects include chest pain, dysphagia and stricture formation. Rare 
complications such as bleeding and perforation have been noted. Randomized sham 
controlled studies have shown high levels of eradication of both non-dysplastic (>90%) and 
dysplastic (>90%) Barrett’s mucosa. 82 Long term follow up studies show the response is 
durable with the majority of patients (>85%) maintaining complete eradication at five years.  
Recommendation 
Long term outcome studies do not yet support ablation in patients without dysplasia. 
(Grade B)  
Are there any treatments that prevent progression of BE to cancer?  
There is limited evidence to support preventive strategies. The choice of anti-reflux therapy 
(i.e. PPIs versus anti-reflux surgery) has not been shown to influence progression to cancer. 
There is interest in the use of COX inhibitors, but to date only small trials have been 
conducted with no clear evidence of benefit. A large randomized controlled trial is being 
conducted to evaluate the efficacy of aspirin to prevent the onset of cancer in patients with 
BE 86. This trial is due to report in 2019.  
Ablation therapies have shown benefit in randomized trials, but only in those who have 
already developed dysplasia. In these individuals, the risk of cancer progression appears to 
be reduced by approximately 50% by both PDT 87 and RFA 88-90, but cancer risk is not 
eliminated. The only randomized trial 91 to evaluate ablation (APC) in non-dysplastic 
Barrett’s Esophagus, failed to show benefit for ablation.  
Recommendation  
Ablation of BE should remain limited to individuals with HGD in BE who are at imminent risk 
of developing esophageal adenocarcinoma. (Grade B)  
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Practice points  
The treatment of gastro-esophageal reflux with either proton pump inhibitors or anti-reflux 
surgery has not been shown to influence progression to esophageal adenocarcinoma.  
There is currently no high-quality evidence supporting the use of COX inhibitors for 
prevention of esophageal adenocarcinoma.  
How frequently should patients with BE undergo endoscopy?  
The aim of surveillance is to detect dysplasia and early cancer for early treatment. 
Endoscopic surveillance in patients with BE is the current standard of practice 8, 9, although 
there is no evidence from randomized controlled trials for its effectiveness. There is, 
however, indirect evidence based on earlier stage and improved survival in EAC patients 
detected at surveillance, although these retrospective studies are subject to potential lead 
and length time bias. 92, 93 
Both the British Society of Gastroenterology (BSG) and American Gastroenterological 
Association (AGA) have published guidelines for endoscopic surveillance of BE. 8, 9 The 
guidelines differ in the criteria for the diagnosis of BE with both requiring a columnar lined 
esophagus (CLE) but the AGA also requiring intestinal metaplasia to be present in biopsies 
from the CLE. This Australian guideline uses the AGA criteria for a diagnosis of BE. British 
and American guidelines also use the grade of dysplasia found at endoscopy to determine 
the timing of the subsequent surveillance endoscopy. These recommendations are based on 
the evidence of an increased risk of esophageal adenocarcinoma with increasing degrees of 
dysplasia. In those with no dysplasia, the BSG guidelines also take into account the absence 
of intestinal metaplasia and short-segment (<3cm) length, both of which appear to be 
associated with a decreased risk of malignant progression. Both guidelines recommend 
biopsies of any visible lesion or mucosal irregularity and quadrantic biopsies. The BSG 
guidelines recommend quadrantic biopsies every 2 cm in all surveillance endoscopies. The 
AGA guidelines recommend Seattle protocol biopsies with quadrantic biopsies every 2 cm 
unless there is suspected or known dysplasia where every 1 cm is recommended. These 
biopsy protocols have been shown to increase the detection of advanced (high grade and 
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early adenocarcinoma) lesions. 94, 95 However, there is low adherence to the protocols 96 
resulting in lower detection rates of dysplasia. 97 
The recommendations of the Australian working group for frequency of surveillance are 
shown in Table 3. The diagnosis of BE requires intestinal metaplasia in biopsies from the 
CLE. Recommendations for CLE without intestinal metaplasia are discussed below.  
Uncertainty regarding risk of low grade dysplasia progression  
The optimum management of patients diagnosed with low grade dysplasia (LGD) is 
uncertain. There is considerable debate about the risks of progression to high grade 
dysplasia or cancer in this group. Population-based studies report cancer progression rates 
of ~0.5% p.a. 51. In contrast, studies undertaken in academic centers in which diagnoses of 
LGD are made only after review by expert gastrointestinal pathologists report progression 
rates up to 13% p.a. 98. Importantly, in those studies, about 85% of patients diagnosed 
originally with LGD were down-staged to non-dysplastic BE upon expert review. Among 
down-staged patients, the progression rate was ~0.5% p.a.  
Endoscopic surveillance in patients with CLE without intestinal metaplasia 
In patients with no intestinal metaplasia or dysplasia detected in biopsies from long-
segment (> 3cm) CLE, endoscopic surveillance as per the protocol for long segment BE is 
recommended (i.e. every 2-3 years). If there is 1-<3cm of CLE without intestinal metaplasia 
or dysplasia, a repeat endoscopy in 3-5 years is suggested with consideration for discharge 
from surveillance if the repeat endoscopy with Seattle protocol biopsies again shows no 
intestinal metaplasia or dysplasia. In patients with CLE less than 1cm without intestinal 
metaplasia or dysplasia on biopsies from the CLE, no endoscopic surveillance is suggested. If 
dysplasia is found in any biopsies from a CLE without intestinal metaplasia, then 
recommendations are as per the protocols for BE with dysplasia. 
Practice points  
In the absence of randomized trial evidence, the frequency of surveillance endoscopy in BE 
can be guided by current practice guidelines.  
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It is advisable to undertake endoscopic surveillance in suitable patients with BE. The 
frequency of surveillance is based on the presence or absence of dysplasia on previous 
Seattle protocol biopsies and length of Barrett’s Esophagus.  
A diagnosis of dysplasia (indefinite, low and high grade) should be confirmed by a second, 
ideally an expert gastrointestinal pathologist. 
Esophageal biopsies should be taken according to the Seattle protocol.  
Is surveillance cost-effective for follow-up of patients with BE? 
A recent systematic review 99 of seven studies 100-106 found inconsistent assessments of the 
value of surveillance, ranging from being cost-effective to highly cost-ineffective. Hence, 
surveillance of all patients with non-dysplastic BE may not be cost-effective, but this may 
change with identification of patients at high risk of progression to EAC .  
Are there groups of patients with non-dysplastic BE that require more frequent 
surveillance?  
Surveillance protocols for patients with BE are based on observational studies.54, 107 
However groups of patients may be identified with high rates of progression, and thus who 
may benefit from more frequent surveillance. Such groups include patients with longer 
segments of BE (>3cm) (Level of Evidence III-2) 53, 54, 56, 107-110, as well as older patients, males 
and smokers. (Level of evidence II, III-2) 48, 55, 57, 111, 112  
Recommendation 
Patients with Barrett's Esophagus length equal to or greater than 3cm may have intensive 
surveillance, possibly every two to three years following the Seattle protocol. (Grade D) 
Are there groups of patients with BE that can be discharged from surveillance?  
There is limited high-quality evidence to address this question with certainty, although 
studies are in progress which may yield risk reducing modifiers. II, III-2, III-3  
Recommendation  
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For patients with < 1cm of columnar lined esophagus that do not have evidence of intestinal 
metaplasia or dysplasia on Seattle protocol biopsy of the segment, endoscopic surveillance 
is not recommended.  (Grade C)  
Practice point 
Patients with evidence of “regression” of BE (i.e. reduced CLE length or absence of intestinal 
metaplasia), can still continue surveillance. 
Patients with significant co-morbidities, or those unable to tolerate procedural intervention 
for dysplasia/EAC, may be considered for discharge from surveillance.  
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Guidelines for BE with dysplasia or early cancer 
What are the endoscopic features of neoplasia (dysplasia and early cancer) within a BE 
segment? 
Because random sampling of quadrantic biopsies every two centimeters suffers from 
sampling error and, at times, limited adherence 97, 113, newer modalities have been 
proposed including chromoendoscopy, electronic image enhancement technologies and 
high magnification platforms. There is limited information as to whether these methods can 
ultimately change patient management. Presently, high resolution white light endoscopy 
(HR-WLE) remains the gold standard in evaluating patients with BE although the newer 
modalities may be used in addition to HR-WLE to improve characterization of lesions. 114 
Thus, it is important to understand the gross morphological features of dysplasia and early 
cancer and if available, apply some of the more advanced imaging methods. 
Given the inconspicuous nature of dysplasia in BE 115, meticulous inspection and attention to 
subtle endoscopic anomalies using the best available imaging equipment and endoscopes 
are warranted. Debris and mucous should be washed off. If there is extensive peristalsis, 
antispasmodic agents can be used. There is some evidence that cancer preferentially occurs 
in the distal Barrett's segment 116 and in the two to five o’clock position in patients with 
shorter segments of BE (<5cm). 117  
All ulcers in BE should be monitored closely for carcinoma. Biopsies should always be taken 
in depressed regions and if negative, repeated after a course of PPI therapy. Visible lumps or 
nodules consisting of HGD suggest a more advanced lesion where more sinister pathology 
may be present. Suspicious lesions visualized on ‘white light overview’ can be interrogated 
further with any of the enhanced imaging techniques described above. It is not yet clear, 
however, whether these modalities can replace biopsies. (Figure 1) 
What is the histological definition and grading of dysplasia in patients with BE? 
Dysplasia is an unequivocal neoplastic transformation of the epithelial cells that is confined 
within the basement membrane of the metaplastic glandular tissue within which it arises. 
Histological features that characterize dysplasia are best identified on standard H&E stained 
sections and comprise cytological changes and/or architectural changes. 118, 119 
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Cytological features involve nuclear changes (such as increase in size, irregular shape, 
increased nucleus:cytoplasmic ratio, nuclear crowding, hyperchromasia, and the presence of 
nucleoli) and cytoplasmic changes such as mucin depletion. Dysplastic cells exhibit increased 
mitotic activity, including atypical forms and surface mitoses. There is typically failure of 
cellular maturation toward the surface of the mucosa, although this is not always the case. 
120 Goblet cell numbers are reduced and dysplastic cells may lose their normal vertical 
polarity. 
Architectural features are irregular gland outline, variability in glandular size, gland 
crowding with ‘back to back’ pattern, and villiform surface contour. None of these 
cytological or architectural features are sufficient to diagnose dysplasia in isolation. Ancillary 
tests (e.g. p53, AMACR and Ki67 stains) have been advocated to aid the diagnosis of 
dysplasia, however at present, conventional H&E examination remains the gold standard. 
Grading of BE dysplasia is best performed on the H&E stain. Pathologists should report BE 
biopsies as fitting into one of four categories. 118, 119, 121-123 The rationale for this tiered 
approach is to stratify patients into categories of increasing risk for development of or 
concurrent presence of esophageal adenocarcinoma. Many papers have shown an 
increasing risk ranging from small (negative for dysplasia) to significant (high grade 
dysplasia). 124 
1. Negative for dysplasia 
2. Indefinite for dysplasia - when the pathologist believes that the biopsy is displaying 
some features of true dysplasia but is unable to exclude a non-neoplastic process as 
the cause of the abnormality. In general the consideration is whether the histological 
features are sufficient to diagnose low grade dysplasia. However, in some situations 
the pathologist is concerned that the features may represent high grade dysplasia. 
The concept of indefinite for high grade dysplasia/adenocarcinoma has not been 
studied specifically, however pathologists recognize a subgroup of indefinite for 
dysplasia where the cytological and/or architectural abnormality is marked but a 
confident diagnosis of HGD cannot be made. In some of these situations the concern 
is that invasive adenocarcinoma may exist.  
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3. Low-grade dysplasia - displays mild to moderate cytologic atypia and, at most, mild 
disturbance of gland architecture. The neoplastic epithelial cells are crowded, 
elongated and hyperchromatic. The cells generally retain their vertical polarity. 
4. High-grade dysplasia - typically displays both architectural abnormality and severe 
cytologic atypia. Aberrant architectural features include glandular crowding, 
branching or budding glands, villiform, cribriform, micropapillary or cystically dilated 
crypt patterns. Cytological features include complete loss of cell polarity, rounded 
enlarged nuclei with irregular thickened nuclear membranes and conspicuous 
nucleoli. Typical and atypical mitotic figures are readily identified at all levels within 
the glands, as well as on the luminal surface. 
Grading of dysplasia is subject to significant interobserver variability 125-127 , especially LGD. 
Interobserver variability among general histopathologists ranges from kappa values of 0.14 
to 0.32. Specialist gastrointestinal histopathologists have better agreement (kappa 0.48-
0.69). 128 When a diagnosis of LGD made by a general histopathologist is reviewed by an 
expert panel, the diagnosis is most often down-graded to ‘negative for dysplasia’.  
These data support the notion that all cases of BE diagnosed as dysplasia (indefinite, low or 
high grade) should be reviewed by at least one expert GI pathologist. 
What are the histological features of early adenocarcinoma of the esophagus? 
Early adenocarcinoma refers to invasion into mucosa or superficial submucosa, but not 
deeper (T1 in the current TNM system). Adenocarcinoma exists when there is invasion 
beyond the basement membrane of the epithelium. The histological features identifying 
that invasion has occurred include: 129, 130 
1. Single neoplastic cells or small clusters of neoplastic cells in the lamina propria. 
2. Complex architectural patterns characterized by solid growth patterns, tight 
cribriform growth pattern, glands with acute angulation in at least one part of their 
outline, and a pattern of anastomosing fusion of small glands.  
3. Neoplastic cells invading overlying squamous epithelium. 
4. Desmoplastic stromal reaction. 
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Significant interobserver variability exists between pathologists in the separation of HGD 
from early invasive adenocarcinoma in biopsy specimens. 131 Recent studies have identified 
a variety of histological patterns that predict invasive adenocarcinoma including solid or 
cribriform growth patterns, ulceration of dysplastic epithelium, abundant neutrophils within 
dysplastic epithelium, dilated neoplastic glands containing necrotic debris, dysplastic 
glandular epithelium being incorporated into squamous epithelium. The risk of 
adenocarcinoma is increased with number of features present. 132  
The histological report of endoscopic mucosal resections should include data that are 
important for clinical management, particularly the identification of patients who should be 
considered for esophagectomy. These are discussed in greater detail in the guidelines for 
reporting esophageal and gastro-esophageal carcinomas provided by the Royal College of 
Pathologists of Australasia 133.  
 
What are the best modalities for accurately staging early esophageal adenocarcinoma?  
Early esophageal adenocarcinomas are those defined as intra-mucosal adenocarcinoma 
(T1a) or superficial submucosal adenocarcinoma (T1b). 114 A more comprehensive sub-
classification of early esophageal cancers has been proposed with mucosal disease and 
submucosal disease divided into three categories respectively (m1-3/4, and sm1-3) based on 
depth of invasion.  
Options for staging of early EAC include: 
1. Endoscopic biopsy 
2. Endoscopic resection (ER) (also known as endoscopic mucosal resection or EMR) 
3. Endoscopic ultrasound (EUS) with or without fine needle aspirate (FNA) 
4. Positron emission tomography-computerized tomography (PET-CT), once the 
diagnosis of cancer has been confirmed 
Endoscopic biopsy is useful, but is subject to sampling error. ER is superior to biopsy and 
results in a change in diagnosis in up to 50% of patients with dysplasia or adenocarcinoma. 
(Level of evidence IV) 134-137 Moreover, ER allows improved pathological staging of HGD and 
23 
 
T1m and T1sm adenocarcinoma as compared with biopsy and endoscopic ultrasound (EUS). 
(Level of evidence IV) 136 138 (Figure 2) Rates of adverse events following ER, such as 
perforation, bleeding and stricturing, are low when performed at expert centers. (Level of 
evidence IV) 138 139, 140. Endoscopic ultrasound is not accurate for determining the stage of 
early esophageal adenocarcinoma, especially distinguishing T1m from T1sm tumors. It is 
useful for differentiating T1 and >T1 stages. (Level of evidence IV) 141, 142 Endoscopic 
ultrasound and EUS-guide fine-needle aspiration (EUS-FNA) are superior to computed 
tomography (CT) for locoregional lymph node staging (Level of evidence IV) 143, 144 
Recommendations 
Endoscopic resection is the most accurate staging modality for early esophageal 
adenocarcinoma for suitable lesions and where appropriate expertise is available. (Grade D)  
Endoscopic ultrasound can be used prior to endoscopic resection when deeper invasion is 
considered likely, particularly for lesions with ulcerated or depressed morphology. (Grade D)  
FDG-PET or PET/CT is not routinely indicated in staging early esophageal adenocarcinoma. It 
is best used for the staging of distant metastases or in cases of suspected more advanced 
local disease. (Grade D)  
  
What is the appropriate management of low grade dysplasia in patients with BE?  
Recent studies suggest that when the diagnosis of LGD is agreed on by two or more expert 
pathologists, the risk of progression to neoplasia is higher than previously reported. (Level 
of evidence III-2) 88, 98, 145 British and American guidelines recommend increased frequency 
of surveillance. 8, 9 Endoscopic ablation with a range of methods is associated with lower 
rates of progression to cancer. (Level of Evidence IV) 146 In particular, an RCT reported that 
RFA in patients with confirmed LGD have significantly lower rates of progression to cancer 
or HGD, although as yet there is no evidence of an overall survival benefit. (Level of 
Evidence II) 88 
Recommendations  
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The diagnosis of LGD should be confirmed by a second pathologist, ideally an expert 
gastrointestinal pathologist. (Grade C)  
In patients with confirmed LGD, it is advised to perform rigorous high definition endoscopy 
or refer to an expert centre for assessment. (Grade C)  
In patients with confirmed LGD, intensified endoscopic surveillance is required. Endoscopic 
ablation may be considered especially where low grade dysplasia is definite, multifocal and 
present on more than one occasion. This decision needs to be individualized, based on 
discussion of risk and benefits with the patient. (Grade B)  
What are the goals of treatment of HGD in patients with BE?  
There is no high level evidence which directly answers this question, and so the guidelines 
are based on expert opinion. As HGD is prone to both over- and under-staging, the first goal 
of management is to confirm the diagnosis. 
Once HGD has been confirmed, the goal of treatment is to prevent the progression to 
malignancy through the removal of dysplastic tissue. More specifically the goals of 
treatment are: 
1. The removal of all dysplastic tissue114 
2. The removal of all Barrett’s metaplasia if possible114 
3. Preservation of normal swallowing/nutrition 
4. Minimization of morbidity due to the eradication technique 
5. Confirmation of the diagnosis of HGD (ie: exclusion of malignancy) through 
examination of resected tissue (endoscopically or surgically), where possible 
6. Continued follow up in patients who have had endoscopic therapy114 
There is no management strategy which perfectly fulfils all these criteria. Current practice 
favors endotherapy (ER or ablation) over surveillance or esophagectomy for HGD/T1a 
cancer although no randomized control trials have compared the two modalities directly. All 
patients should be discussed at a multidisciplinary meeting. 
Practice point  
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The confirmation of HGD should act as a trigger for definitive treatment. 
What is the best endoscopic treatment for HGD in patients with BE?  
Endoscopic mucosal resection alters histological grade or local T stage in 48% of patients 
and reduces esophagectomy rates by providing an effective local therapy. ER has a high 
success rate (94%) for complete Barrett's excision in short segment BE. (Level of Evidence 
IV) 139 Radiofrequency ablation has been shown to completely eradicate HGD in 81% of 
patients at one year of follow-up vs 19% complete eradication in patients undergoing 
endoscopic surveillance alone. Similar outcomes are reported following radiofrequency 
ablation at two and three-years of follow-up with 95% and 96% complete eradication, 
respectively. (Level of Evidence II) 89, 90 (Figure 3) 
Recommendations 
ER should be considered for patients with intramucosal adenocarcinoma or HGD and 
visible/nodular lesions. (Grade D)  
RFA should be considered for patients with HGD within flat segments of Barrett's 
esophagus. RFA is not appropriate in patients with visible abnormalities, these should be 
treated by ER. RFA may be the preferred treatment strategy over ER for patients with long 
segment BE or circumferential Barrett's due to a lower rate of stricture formation. (Grade B)  
Practice point  
It is advisable to refer patients with BE and dysplasia or early EAC to tertiary referral centers 
for management.  
What is the best endoscopic management of early esophageal adenocarcinoma?  
Early EAC comprises the histological tumor classification of T1a (invasion into the mucosa) 
and T1b (invasion into submucosa but not muscularis propria). The depth of invasion can be 
further stratified based on mucosal (m1-m3 / m1-m4) or submucosal (sm1-sm3) 
involvement. 123, 147 Endoscopic resection is the most accurate T staging modality for early 
EAC. (Level of Evidence IV) 137, 139 (Figure 4) The risk of lymph node involvement with T1a 
and T1b early EAC is 1.3-2.5% and 12-31% respectively. 148-151 Unlike locally advanced or 
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node-involving disease, early EAC can often be cured with surgical or endoscopic 
approaches. Endoscopic treatment is less morbid and expensive than esophagectomy, and is 
organ preserving. 152 Endoscopic mucosal resection is effective for T1a early esophageal 
adenocarcinoma when performed in experienced centers. Selected patients with T1b early 
esophageal adenocarcinoma may benefit from endoscopic resection if esophagectomy is 
not indicated. (Levels of Evidence II, III-2, IV) 153, 154 155-157  
Recommendations  
All lesions and visible abnormalities should be staged by focal endoscopic resection. (Grade 
D)  
If endoscopic resection of early EAC is planned, endoscopic mucosal resection is appropriate 
in most cases. Ablative therapies should not be used as primary endoscopic therapy for 
early esophageal adenocarcinoma. (Grade C)  
Patients with T1a adenocarcinoma on endoscopic work-up should be offered endoscopic 
resection in preference to esophagectomy. (Grade D) Selected patients with T1b early EAC 
may also be offered endoscopic resection, but only if esophagectomy is not indicated. 
(Grade D)  
Following resection of early esophageal adenocarcinoma the remaining Barrett’s mucosa 
should be eradicated. Barrett’s eradication options include complete endoscopic resection, 
radiofrequency ablation, cryotherapy and argon plasma coagulation. (Grade C) 
Following resection of early esophageal adenocarcinoma the patient should undergo regular 
and careful surveillance examinations. (Grade C)  
Practice point  
Endoscopic resection of early EAC should be performed in referral centres that have 
integrated expertise in endoscopy, imaging, surgery, and histopathology.  
Careful and dedicated endoscopic interrogation of all Barrett’s mucosa is advised.  
After successful endoscopic treatment for BE neoplasia, how frequently should patients 
undergo endoscopy?  
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There is no high level evidence which directly answers this question, and so the guidelines 
are based on expert opinion. Following endoscopic treatment for BE with neoplasia, 
patients should be considered for three monthly surveillance endoscopies with Seattle 
protocol to confirm clearance of disease. Once clearance has been achieved, consider 6 
monthly endoscopic surveillance for one year, then annually. Higher risk patients may 
require closer surveillance endoscopy after clearance of BE neoplasia is achieved (i.e. 
initially 3 monthly for a year). Endoscopic resection of mucosal irregularities (nodules, 
depressed areas) in the squamous epithelium should be considered to clarify possible 
recurrent or metachronous intramucosal adenocarcinoma from subsquamous glands.  
Practice point  
Consider three monthly surveillance endoscopy with Seattle protocol during the endoscopic 
treatment phase to confirm clearance of intramucosal adenocarcinoma and residual 
Barrett’s esophagus. Once clearance has been achieved, consider 6 monthly endoscopic 
surveillance for one year, then annually.  
Higher risk patients may require closer surveillance endoscopy after clearance of BE 
neoplasia is achieved (i.e. initially 3 monthly for a year). Endoscopic resection of any 
nodularity in the squamous epithelium should be considered to clarify possible recurrent or 
metachronous cancer from subsquamous glands.  
What endoscopic surveillance protocol should be followed for patients with high grade 
dysplasia?  
Surveillance is generally not indicated for patients with HGD and therapeutic intervention 
must be considered instead.  
 
How effective is endoscopic management compared with surgical management for HGD in 
patients with BE?  
There are no randomized controlled trials comparing surgery with endoscopic treatments 
for HGD. Evidence therefore comes largely from non-randomized retrospective studies. 
These studies report that endoscopic treatment of HGD provides similar outcomes to 
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surgery with regard to overall survival and cancer related mortality. (Level of Evidence III-2) 
153, 158-162. In addition, the studies tend to report that compared to surgery, endoscopic 
treatments result in less morbidity but higher rates of local recurrence. (Level of Evidence 
III-2) 153, 158-162 
Recommendation 
Patients with HGD in BE should be managed in centers with high volume experience of the 
condition. The treatment and follow-up should occur in those specialist centers. (Grade C)  
Practice points  
Patients with HGD in BE can be discussed at a multidisciplinary team meeting at a specialist 
centre.  
Endoscopic treatment will be the first line treatment option for the majority of patients with 
HGD in Barrett's Esophagus. There will be a group of patients for whom endoscopic 
treatment is not appropriate or successful and they will be best treated with surgery in a 
specialist centre.  
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Figure 1 – 
 (1A) –C0M3 Barrett’s esophagus containing a 2x1 cm (Paris 0–Is) lesion at 6 o’clock in white light and in (1B) as seen with narrow band imaging. (1C) – Flat C2M4 Barrett’s esophagus (1D) – Closer examination using narrow band imaging reveals a focal area with irregular capillary and mucosal pattern at 12 o’clock    
45 
 
Figure 2 – 
 (2A)- C3M4 Barrett’s esophagus. After careful inspection a focal abnormality was noted at 2 o’clock. (2B)- Focal endoscopic mucosal resection was performed for staging confirming high grade dysplasia (2C)- C7M8 Barrett’s esophagus. Using a distal attachment cap for improved visualisation, nodular lesion with slight depression (Paris 0–IIa+IIc) noted at 12-2 o’clock.  (2D)- This area is completely excised by endoscopic mucosal resection. Histology confirmed Barrett’s esophagus with high grade dysplasia and focal area of intramucosal adenocarcinoma (M1-T1a)           
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Figure 3 – 
  (3A)- C5M7 Barrett’s esophagus with high grade dysplasia previously treated by endoscopic mucosal resection and radiofrequency ablation – residual disease remaining at 7 o’clock proximally and 12-4 o’clock distally. (3B)- Focal radiofrequency ablation to sites of residual Barrett’s mucosa.  (3C)- C2M4 Barrett’s esophagus previously treated by radiofrequency ablation for flat high grade dysplasia. (3D)- Residual Barrett’s mucosa is treated by focal radiofrequency ablation.          
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Figure 4 – 
 (4A)- C4M5 Barrett’s esophagus with diffuse nodular mucosa between 9 and 2 o’clock. (4B)- Close up examination using narrow band imaging discloses irregular mucosa with abnormal capillary and pit patterns. (4C)- The abnormal area is removed by multiband mucosectomy, this revealed intramucosal adenocarcinoma (T1a) (4D)- On progress examination at 6 weeks neosquamous epithelium is seen in the area of excision. (4E)- Further stepwise complete endoscopic resection for the residual Barretts mucosa is performed resulting in a hemi-circumferential mucosal defect.  (4F)- 6 weeks following the previous resection there is extensive neo-squamous re-epithelialisation of the distal esophagus. A small residual segment of Barrett’s mucosa remains. The patient had low grade dysphagia from this stricture which was easily treated with Savary dilation.     
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Table 1: Hierarchy of evidence recommendation†  
Level  Description 
 I A systematic review of level II studies  
 II  A randomized controlled trial (intervention) or a prospective cohort study 
(etiology) 
 III-1  A pseudo-randomized controlled trial (intervention) or all or none design 
(etiology)  
 III-2  A comparative study with concurrent controls (intervention) or a 
retrospective cohort study (etiology) 
 III-3 A comparative study without concurrent controls (intervention) or a case-
control study (etiology) 
 IV  Case series with either post-test or pre-test/post-test outcomes or a cross-
sectional study  
†adapted from the National Health and Medical Research Council of Australia 
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Table 2: Body of evidence recommendation † 
Grade Description 
A  Body of evidence can be trusted to guide practice  
B  Body of evidence can be trusted to guide practice in most situations  
C  Body of evidence provides some support for recommendation(s) but care 
should be taken in its application  
D  Body of evidence is weak and recommendation must be applied with 
caution 
Practice point Where no good-quality evidence is available but there is consensus 
among Expert working group members, so-called “Practice points” are 
given 
†adapted from the National Health and Medical Research Council of Australia 
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Table 3: Recommended frequency of endoscopic surveillance of patients with BO  
NO DYSPLASIA † ON ENDOSCOPIC ASSESSMENT AND SEATTLE PROTOCOL BIOPSY ‡ 
Short (<3cm) segment  Repeat endoscopy in 3-5 years.  
Long (≥ 3cm) segment  Repeat endoscopy in 2-3 years.  
†   If there has been previous low grade dysplasia, see low grade dysplasia protocol.  
‡ Seattle protocol - biopsy of any mucosal irregularity and quadrantic biopsies every 2cm 
unless know or suspected dysplasia then quadrantic biopsies every 1 cm. 
INDEFINITE FOR DYSPLASIA ON BIOPSY 
The changes of indefinite for dysplasia on biopsy should be confirmed by a second 
pathologist, ideally an expert gastrointestinal pathologist. If indefinite for dysplasia is 
confirmed, then the following endoscopic surveillance is recommended:  
1. Repeat endoscopy in 6 months with Seattle protocol biopsies for suspected dysplasia 
(biopsy of any mucosal irregularity and quadrantic biopsies every 1cm) on maximal 
acid suppression.  
2. If repeat shows no dysplasia then follow as per non-dysplastic protocol.  
3. If repeat shows low grade or high grade dysplasia or adenocarcinoma then follow 
protocols for these respective conditions.  
4. If repeat again shows confirmed indefinite for dysplasia, then repeat endoscopy in 6 
months with Seattle protocol biopsies for suspected dysplasia.  
LOW GRADE DYSPLASIA ON BIOPSY 
The changes of low grade dysplasia on biopsy should be confirmed by a second pathologist, 
ideally an expert gastrointestinal pathologist. If low grade dysplasia is confirmed, then the 
following endoscopic surveillance is recommended:  
1. Repeat endoscopy every 6 months with Seattle protocol biopsies for dysplasia 
(biopsy of any mucosal irregularity and quadrantic biopsies every 1cm).  
2. If two consecutive 6 monthly endoscopies with Seattle dysplasia biopsy protocol 
show no dysplasia, then consider reverting to a less frequent follow up schedule.  
HIGH GRADE DYSPLASIA OR ADENOCARCINOMA ON BIOPSY 
Referral to a centre that has integrated expertise in endoscopy, imaging, surgery and 
histopathology.  
 
 
